Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (F:GU5) — Market Cap & Net Worth
Market Cap & Net Worth: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5)
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (F:GU5) has a market capitalization of $429.33 Million (€367.23 Million) as of August 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #12963 globally and #1373 in its home market, demonstrating a -3.47% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's stock price €1.67 by its total outstanding shares 219900000 (219.90 Million). See Guangzhou Baiyunshan Pharmaceutical Hold capex to cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Market Cap History: 2015 to 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's market capitalization history from 2015 to 2026. Data shows growth from $50.54 Million to $429.33 Million (22.07% CAGR).
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.17x
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's market cap is 0.17 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $57.10 Million | $20.04 Billion | $1.51 Billion | 0.00x | 0.04x |
| 2017 | $66.59 Million | $20.95 Billion | $2.06 Billion | 0.00x | 0.03x |
| 2018 | $96.79 Million | $42.23 Billion | $3.44 Billion | 0.00x | 0.03x |
| 2019 | $102.29 Million | $64.95 Billion | $3.19 Billion | 0.00x | 0.03x |
| 2020 | $91.99 Million | $61.67 Billion | $2.92 Billion | 0.00x | 0.03x |
| 2021 | $157.88 Million | $69.01 Billion | $3.72 Billion | 0.00x | 0.04x |
| 2022 | $262.49 Million | $70.79 Billion | $3.97 Billion | 0.00x | 0.07x |
| 2023 | $334.26 Million | $75.52 Billion | $4.06 Billion | 0.00x | 0.08x |
| 2024 | $550.16 Million | $74.99 Billion | $2.84 Billion | 0.01x | 0.19x |
| 2025 | $501.32 Million | $77.66 Billion | $2.98 Billion | 0.01x | 0.17x |
Competitor Companies of GU5 by Market Capitalization
Companies near Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in the global market cap rankings as of August 5, 2026.
Key companies related to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited by market ranking:
- McKesson Corporation (NYSE:MCK): Ranked #274 globally with a market cap of $94.62 Billion USD.
- Cencora Inc. (NYSE:COR): Ranked #529 globally with a market cap of $50.53 Billion USD.
- Cardinal Health Inc (NYSE:CAH): Ranked #632 globally with a market cap of $43.01 Billion USD.
- Sigma Healthcare Ltd (AU:SIG): Ranked #1086 globally with a market cap of $24.26 Billion USD ( AU$34.28 Billion AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #274 | McKesson Corporation | NYSE:MCK | $94.62 Billion | $830.43 |
| #529 | Cencora Inc. | NYSE:COR | $50.53 Billion | $306.28 |
| #632 | Cardinal Health Inc | NYSE:CAH | $43.01 Billion | $233.55 |
| #1086 | Sigma Healthcare Ltd | AU:SIG | $24.26 Billion | AU$2.97 |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's market cap moved from $50.54 Million to $ 429.33 Million, with a yearly change of 22.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €429.33 Million | -14.36% |
| 2025 | €501.32 Million | -8.88% |
| 2024 | €550.16 Million | +64.59% |
| 2023 | €334.26 Million | +27.35% |
| 2022 | €262.49 Million | +66.26% |
| 2021 | €157.88 Million | +71.63% |
| 2020 | €91.99 Million | -10.08% |
| 2019 | €102.29 Million | +5.68% |
| 2018 | €96.79 Million | +45.37% |
| 2017 | €66.59 Million | +16.61% |
| 2016 | €57.10 Million | +12.97% |
| 2015 | €50.54 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 5th, 2026 the market cap of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $429.33 Million USD |
| MoneyControl | $429.33 Million USD |
| MarketWatch | $429.33 Million USD |
| marketcap.company | $429.33 Million USD |
| Reuters | $429.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally. The company operates through Modern Chinese Medicine Business, Chemical Pharmaceutical Technology Business, Natural Beverage Business, Pharmaceutical Commercial Business, and Other segments. It is involved in the research, develo… Read more